Michel Alexandra, Dorval Michel, Chiquette Jocelyne, Savard Josée
School of Psychology, Université Laval, Québec, Canada.
CHU de Québec-Université Laval Research Center, Québec, Canada.
Hered Cancer Clin Pract. 2024 Aug 27;22(1):16. doi: 10.1186/s13053-024-00285-5.
Fear of cancer recurrence (FCR) affects virtually all patients who have been treated for cancer, to varying degrees. Breast cancer survivors who carry a BRCA1 or BRCA2 gene mutation are at high risk of cancer recurrence. No study has yet assessed FCR specifically in this population.
This cross-sectional study, conducted in women who were treated for breast cancer and carrying a BRCA1/2 mutation, aimed to: (1) assess the mean level of FCR and estimate the proportion of patients with clinical levels of FCR; (2) examine the relationships between FCR and selected psychological variables (e.g., avoidance, intolerance to uncertainty) and quality of life; (3) explore whether FCR levels vary as a function of the past preventive treatment received; and (4) to assess the associations between FCR and the presence of decisional conflict or regret regarding the various preventive options.
Participants were recruited through an e-mail sent to an oncogenetic network mailing list (Réseau ROSE). Participants were asked to complete a battery of questionnaires online assessing FCR and other psychological and quality of life variables.
A total of 89 women completed the survey. Most participants had undergone a preventive mastectomy (62.9%) and a preventive salpingo-oophorectomy (75.3%) at the time of the study. The mean Fear of Cancer Recurrence Inventory-severity score was 16.8, which exceeds the clinical cut-off score of 13, and 70.8% of the participants showed a clinical level of FCR. FCR was significantly associated with higher levels of anxiety and depression, and higher avoidance and intolerance of uncertainty, but not with quality of life. No significant difference was observed on the total FCR score between women who had received preventive surgery (mastectomy and/or salpingo-oophorectomy) and those considering it, and those not considering it. The association was significant between higher FRC scores and greater decisional conflicts and regrets about choosing to undergo preventive surgery.
These data suggest that FCR is a significant problem for breast cancer survivors carrying a BRCA1/2 genetic mutation, even after undergoing a prophylactic surgery. This highlights the importance of providing these women with specific psychological intervention focusing on FCR.
癌症复发恐惧(FCR)几乎影响到所有接受过癌症治疗的患者,程度各异。携带BRCA1或BRCA2基因突变的乳腺癌幸存者癌症复发风险很高。尚无研究专门评估这一人群的FCR。
这项横断面研究针对接受过乳腺癌治疗且携带BRCA1/2基因突变的女性开展,旨在:(1)评估FCR的平均水平并估计具有临床水平FCR的患者比例;(2)研究FCR与选定心理变量(如回避、对不确定性的不耐受)及生活质量之间的关系;(3)探讨FCR水平是否因过去接受的预防性治疗而有所不同;(4)评估FCR与对各种预防性选择存在决策冲突或遗憾之间的关联。
通过发送至肿瘤遗传网络邮件列表(Réseau ROSE)的电子邮件招募参与者。要求参与者在线完成一系列问卷,评估FCR及其他心理和生活质量变量。
共有89名女性完成了调查。在研究时,大多数参与者已接受预防性乳房切除术(62.9%)和预防性输卵管卵巢切除术(75.3%)。癌症复发恐惧量表严重程度平均得分是16.8,超过了临床临界值13,70.8%的参与者表现出临床水平的FCR。FCR与更高水平的焦虑和抑郁、更高的回避及对不确定性的不耐受显著相关,但与生活质量无关。在接受预防性手术(乳房切除术和/或输卵管卵巢切除术)的女性、考虑接受预防性手术的女性以及不考虑接受预防性手术的女性之间,FCR总分未观察到显著差异。FRC得分越高与对选择接受预防性手术的更大决策冲突和遗憾之间的关联显著。
这些数据表明,对于携带BRCA1/2基因突变的乳腺癌幸存者,即使在接受预防性手术后,FCR仍是一个重大问题。这凸显了为这些女性提供针对FCR的特定心理干预的重要性。